Sydney, Australia – GenesisCare has today announced the appointment of Dr Brian McNamee as the new Chairman of its Board.
Previously an advisor to the CEO and Board, Dr McNamee takes on the role commencing immediately with previous Chairman, Mr. David Vaux, stepping down recently after 10 years as Chairman.
“We are delighted to welcome Brian to Chair GenesisCare and take us to the next phase of international expansion and healthcare innovation,” CEO and Founder of GenesisCare, Dan Collins said.
“As we expand into Asia and across Europe, and with new treatments in development for patients with cancer or heart disease, Brian can provide a unique capability to make us better”.
“Our staff and doctors are committed to improve patient access and quality for those with cancer or heart disease and Brian understands what we are about and what it takes to get this right globally at scale,” Mr Collins said.
Dr McNamee said he was excited to join the Board and Chair an industry leading company in GenesisCare.
“GenesisCare has a clear purpose to improve patient access and outcomes and this Australian founded company has a chance to have a profound and positive impact on healthcare outcomes globally”.
“It’s exciting to work closely with the founding CEO Dan Collins, the Board, and Dan’s leadership team,” Dr McNamee said.
“Through a focus on patient care; through innovation, entrepreneurship and by partnering well with government and global technology providers – GenesisCare is expanding world class care to patients across Australia and the globe.”
Dr McNamee said he would like to recognise the contribution of the previous Chairman of ten years, Mr. David Vaux, and the many doctor leaders, managers and committed staff that have contributed to the development and success of GenesisCare over almost 15 years.
Dan Collins said he was excited by what Dr McNamee’s leadership and experience will mean for GenesisCare, particularly as it set about implementing a new global and strategic agenda.
“Our promise is to get the best possible life outcomes for our patients. This involves finding new and better ways to treat cancer and heart disease,” Mr. Collins said.